0
0
A team led by Rickard Strandberg and Hannes Hagström at Karolinska Institutet developed the CORE (Cirrhosis Outcome Risk Estimator) model using data from population-based cohorts in Sweden and Finland. Leveraging advanced statistical modeling, the test integrates independent predictors—the patient’s age, sex, and levels of three common liver enzymes measured in routine blood panels—to accurately estimate the risk of major adverse liver outcomes (MALO), such as cirrhosis, liver failure, and liver cancer, within a 10-year window. The model was validated across different European populations and demonstrated striking accuracy, with an 88% ability to correctly predict individuals who would develop severe liver disease.
Unlike existing diagnostic methods such as Fibroscan or invasive liver biopsy, which are often only used after symptoms emerge or in high-risk groups, the CORE score can be applied easily in primary care settings by general practitioners. Its reliance on routine blood tests means it can be implemented widely and cost-effectively, potentially enabling earlier clinical interventions that improve outcomes.
A web-based calculator has been made available freely for clinicians at www.core-model.com to facilitate use in everyday clinical practice.
Understanding the Blood Markers
The three enzymes measured—AST, ALT, and GGT—are standard liver function tests commonly evaluated in routine health assessments. They indicate liver cell injury (AST and ALT) and cholestasis or bile duct function (GGT). Elevated levels of these enzymes can reflect liver inflammation, fat accumulation, or early fibrosis, all precursors to severe liver disease.mayoclinic+1
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT): Indicators of liver cell injury; raised levels may indicate hepatitis, fatty liver disease, alcohol-related damage, or drug toxicity.
-
Gamma-glutamyl transferase (GGT): Reflects cholestatic injury or bile duct problems and may also be elevated in alcohol use or certain medications.
The addition of demographic factors like age and sex improves the model’s precision since liver disease risk varies substantially by these parameters.
Expert Commentary
Dr. Richard Thompson, a hepatologist not involved in the study, commented: “The development of the CORE risk score represents a significant advancement in liver disease management. By using parameters already commonly available in primary care, it allows early identification of patients at risk well before clinical symptoms arise. This is crucial because liver disease often progresses silently until advanced stages when treatment options are limited.” He highlighted this test’s potential to shift focus from reactive to proactive care.
Professor Emily Chen, a public health expert, noted: “Given the rising global burden of liver disease driven by factors like obesity, alcohol use, and viral hepatitis, accessible tools like CORE are urgently needed for effective population screening and timely preventive measures.”
Broader Context and Public Health Implications
Severe liver diseases, including cirrhosis and hepatocellular carcinoma, represent major causes of morbidity and mortality worldwide, often diagnosed late due to their initially asymptomatic nature. Early detection remains a challenge, hampering timely interventions such as lifestyle changes, antiviral therapies, or surveillance for liver cancer.
The CORE model’s simplicity and reliance on standard blood tests mean it can be integrated into routine health checks, particularly benefiting primary care where most patients first seek medical attention. Early identification of high-risk individuals may prompt further diagnostic evaluation, lifestyle counseling, or specialized referral, ultimately improving survival chances and reducing healthcare costs.
The World Health Organization emphasizes the need for scalable screening tools as liver diseases increase globally, especially linked to metabolic syndrome and alcohol consumption.
Limitations and Balanced Perspectives
While promising, the CORE risk score has some limitations. It primarily predicts risk over a 10-year horizon but may miss very early or rare liver diseases not reflected by enzyme changes. False positives and negatives can occur, necessitating confirmatory testing.
Additionally, enzyme levels can fluctuate due to various transient conditions unrelated to chronic liver disease; thus, clinical judgment remains essential. The model is currently validated mainly in European populations, and further studies are needed to confirm its applicability across diverse ethnic and geographic groups.
Some experts caution that reliance on blood tests alone cannot replace comprehensive clinical evaluation, imaging, and other diagnostic approaches but serve as an adjunct tool.
Practical Takeaways for Readers
For the general public, this breakthrough means liver health can be assessed more easily and earlier through routine blood work during regular medical checkups. Individuals with risk factors such as obesity, diabetes, high alcohol use, or family history should ensure they have regular liver enzyme tests.
For healthcare professionals, the CORE risk score offers a user-friendly tool to stratify risk and guide decision-making in primary care.
Maintaining a healthy lifestyle, avoiding excessive alcohol, managing metabolic health, and following medical advice remain key to liver disease prevention.
Medical Disclaimer
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
